Discriminatory metabolic and inflammatory parameters in serum and omental adipose tissue of obese patients with different insulin sensitivity

Marian Khatib¹, Isabel Zvibel²,³,¹, Shira Zelber-Sagiv¹,⁴, Chen Varol¹,³, Guy Lahat¹, Subhi Abu-Abeida¹, Joseph M. Klausner²,³,⁴, Zamir Halpern³,⁴, Sigal Fishman²,³

¹Surgery Department, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
²The Research Center for Digestive Tract and Liver Diseases, Tel-Aviv Sourasky Medical Center, Israel
³Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
⁴School of Public Health, Haifa University, Haifa, Israel

A R T I C L E   I N F O

Article history:
Received 1 June 2014
Received in revised form
25 June 2014
Accepted 9 July 2014

Keywords:
Insulin resistance
Inflammatory markers
Bile acids
ADAM17
Adipokines
Cytokines

A B S T R A C T

Objective: Metabolically healthy obese phenotype is defined by high insulin sensitivity and lack of metabolic syndrome, parameters regulated by omental adipose tissue inflammation, ectopic fat deposition and adipose tissue dysfunction. Our study aimed to identify novel metabolic and inflammatory markers in serum and omental adipose tissue which characterize the “unhealthy” obese patients and distinguish them from obese patients with better metabolic profile.

Design: Cross-sectional study.

Patients: Subjects included 75 obese patients undergoing bariatric surgery at the Tel-Aviv Medical Center (mean age 43.9 ± 13.9, mean BMI 41 ± 8.4). The HOMA median value was used as a cut-off to differentiate between patients with better or worse insulin resistance.

Measurements: Demographic data, fasting serum insulin, glucose, bile acids, serum metabolic and inflammatory markers were obtained. During the bariatric surgery, omental adipose tissue was harvested and analyzed for metabolic and inflammatory markers using qRT-PCR. Logistic regressions were used to calculate odds ratio and 95% confidence interval for the prediction of the metabolic profile.

Results: Serum markers that were significantly higher among the obese with HOMA >6 were total bile acids. In the omental adipose tissue the inflammatory markers TNFs and ADAM17 were significantly higher among obese patients with HOMA >6. In multivariate analysis, the strongest predictor for insulin resistance was ADAM17 (OR = 1.82, 1.06–3.14, P = 0.031).

Conclusions: The study highlighted the predictive value of serum bile acids in identifying obese patients at high risk. Secondly, omental adipose tissue ADAM17 was revealed as a novel and strongest independent predictor for higher insulin resistance in morbidly obese patients.

© 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Introduction

Obesity is associated with increased risk of developing metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) leading to higher all-cause mortality. However, accumulating evidence suggests that not all obese subjects are at increased cardiometabolic risk and that the “metabolically healthy obese” (MHO) phenotype may exist [1]. These individuals are defined as having metabolically benign obesity [2] with high levels of insulin sensitivity, normal lipid and inflammation profiles and are normotensive, despite excessive body fatness [3–5].

The molecular basis for this phenotype is not well understood but is likely to involve reduced inflammatory responses [6].
Primeau et al. have reported a number of characteristics of the MHO phenotype, including lower omental fat accumulation, higher birth weight, adipose cell size, and gene expression–encoding markers of adipose cell differentiation [7]. Recent studies suggest that inflammation of omental adipose tissue, ectopic fat deposition and adipose tissue dysfunction mediate IR in human obesity independently of total body fat mass. This suggests that mechanisms beyond a positive caloric balance, such as inflammation and adipokine release determine the pathological metabolic consequences in patients with obesity [8].

So far, there is still limited data regarding the determinants of the MHO phenotype, which would shed light on the pathogenesis of metabolic alterations in obesity and would help in the development of new therapeutic interventions tailored to obese individuals with specific metabolic phenotype.

In the present study, we aimed to identify inflammatory and metabolic markers in serum and omental adipose tissue of morbidly obese patients which correlate with better or worse insulin resistance state. In addition, we sought whether there were any significant associations between certain metabolic and inflammatory markers.

**Experimental design & methods**

**Study design and population**

We have performed cross-sectional study in a cohort of seventy five morbidly obese patients attending the obesity clinic at the Tel-Aviv Medical Center and that underwent a bariatric surgery. All data were collected prospectively. Exclusion criteria were: type-2 diabetes treated with insulin and type-1 diabetes. The HOMA was calculated as fasting serum insulin (µU/ml) × fasting plasma glucose [mmol/l]/22.5 [9] served in the definition of the MHO (divided to percentiles as accepted [1]).

**Serum tests**

Serum was drawn from fasted patients before their bariatric surgery and kept frozen in aliquots at −80 °C. Serum adipokines and inflammatory cytokines (adiponectin, IL-6, resistin, progranulin) were detected by ELISA (R&D systems). Other metabolic and liver function tests (including bile acids) were assayed at the local chemistry lab. Insulin was assessed by RIA at the endocrinology lab and in the Corbett rotor light cycler (Corbett Robotics Pty Ltd, Brisbane, Australia). The primers used were:

Lipoprotein lipase (LPL): 5'-GGGATCTTGGACATTTACC-3', 5'-CTGGTGGGACGTCTACA-3';

CIDEA: 5'-CTGGCAAGGGGATAACGTGT -3', 5'-GTCTGGTGGGATCTTGGCTT -3';

CIDE: 5'-CCAACATGACAGGAGCAG -3', 5'-TCTTCTCCAGCACCAGTG -3';

**Table 1**

| Characteristic | n = 75 | Distribution |
|----------------|-------|-------------|
| Age (years)    | 43.89 ± 13.88 |
| Gender (% men) | 30.7 |
| BMI (kg/m²)    | 41.04 ± 8.36 |
| Diabetes (%)   | 24.3 |
| Oral diabetic medication (%) | 12 |
| HOMA (score)   | 8.10 ± 7.17 |
| Insulin (µU/ml) | 33.81 ± 24.68 |
| ALT (U/l)      | 14.88 ± 18.49 |
| AST (U/l)      | 23.07 ± 12.44 |

**Quantitative real time RT-PCR from omental adipose tissue**

Omental fat was taken from patients that signed the informed consent form for fat biopsy (not all subjects that agreed for their sera to be used agreed to have biopsies of fat taken) during the bariatric surgery and was used to extract total RNA using the bariatric surgery and was used to extract total RNA using the RNeasy Lipid tissue kit (Qiagen) and 2.5 µg total RNA was reverse-transcribed using M-MLV (Promega, Madison, WI). Real time RT-PCR (qRT-PCR) was performed using the Absolute Blue QPCR chemistry lab. Insulin was assessed by RIA at the endocrinology lab and in the Corbett rotor light cycler (Corbett Robotics Pty Ltd, Brisbane, Australia).

**Table 2**

| Characteristic | n = 75 | Distribution |
|----------------|-------|-------------|
| Perilipin (plin): 5'- GAGATCTCCTCCTCCCTCCAG -3', 5'-TCCTCAGGGGTATCGAGAG - 3'; 11β-hydroxysteroid dehydrogenase type 1 (HSD1B1): 5'-AGAGCAATTTTGTGCGTGAGAG -3', 5'-AATGCTTCCATTGCTTCTG -3'; Progranulin (PRGN): 5'-GCCAATCTCCTGACCTTACC -3', 5'-GATCTTTGGAAGCAGGATCG -3'; Sorbitolin: 5'-CATTTGGGGCTTCACAGAAT -3', 5'-TTCAGGGTCTTGAGACTG -3'; IL-6: 5'-TACCCTCAGAGAAAGATCC -3', 5'-TTTCTCTGCAGCCCTCCTT -3'; GIP receptor (GIPR): 5'-CAATGGGACCTGGGAAGAG -3'; TNFα: 5'-TCAGCCTTCTCCTCCTTG -3', 5'-GCAAGGGGCTATTAGAGA -3'; ADAM17: 5'-GAGGACAGGAGAGGGAATA -3', 5'-CTTACTCACCCTCGAGCTT -3'; CACCTCGACTGTC -3'; TIMP3: 5'-AGGAGCCTTCTCCTCACA -3', 5'-CTTACACTGCTT -3'; GATGTGTAG -3'; Fractalkine: 5'-TGACGCAAATGGACAGATCA -3', 5'-CTGCGGCTTGGTCTCCCA -3'; Osteopontin (OPN): 5'-GCTAAAACCTGACACATCT -3', 5'-GTCAATTGGCTGCTGGTGCT -3'; CCL2: 5'-CCACCATCACCCTGCTGTATT -3', 5'-AGATCTCCCTGGGCAACATG -3'; CCL8: 5'-AGCCACTTTTCACGGCTTCAG -3', 5'-TCTCCAGCCTTGTGATAGGA -3'; CCL20: 5'-TTATTGTTGGGCCTCAACG -3', 5'-TCACCCTGTTGGATAAAGA -3', 5'-TCTGGTTGCTG -3'; RPLP0: 5'-CCCGAGAAGACCTCCTTTT -3', 5'-AGGAAAGGAGGAGATGTT -3';

**Statistical analysis**

Statistical analyses were performed using SPSS version 21. Continuous variables are presented as means ± SD.

To test differences in continuous variables between the two groups of metabolic status, the independent samples t-test and, if necessary, for non-normally distributed variables, the nonparametric Mann–Whitney test were performed (as depicted in Table 2).

Associations between nominal variables were performed with the Pearson Chi–Square test. Correlations between continuous variables were calculated with the Pearson or spearman correlation. A multivariate logistic regression analysis was performed to test the gender adjusted association between the metabolic and inflammatory parameters and the metabolic phenotype. The variables that remained significantly associated with elevated HOMA with adjustment for gender, were further tested in an expanded multivariate analysis (with a stepwise entry) aimed to define the
Table 2
Comparison of patients with HOMA above and below the median (mean ± SD, unless otherwise stated)

| Variable                  | HOMA below median (n = 30) | HOMA above median (n = 29) | P value |
|---------------------------|----------------------------|---------------------------|---------|
| Age (years)               | 42.45 ± 14.37              | 43.45 ± 10.31             | 0.762   |
| Gender (% men)            | 13.3 (n = 30)              | 51.7 (n = 29)             | 0.002   |
| BMI (kg/m²)               | 42.79 ± 7.52               | 42.88 ± 6.53              | 0.850*  |
| ALT (U/l)                 | 10.63 ± 4.73               | 15.50 ± 9.82              | 0.021   |
| AST (U/l)                 | 19.93 ± 7.17               | 24.34 ± 10.66             | 0.066   |
| Diabetes %                | 20.0                       | 39.3                      | 0.107   |
| HOMA (score)              | 4.46 ± 1.21                | 12.53 ± 9.13              | <0.001  |
| Serum markers             |                            |                           |         |
| IL-6 (pg/ml)              | 7.22 ± 4.26                | 7.09 ± 2.57               | 0.005   |
| Resistin (ng/ml)          | 10.44 ± 4.75               | 10.31 ± 3.86              | 0.930   |
| Adiponectin (ug/ml)       | 2.67 ± 1.25                | 4.01 ± 2.30               | 0.060   |
| Total GIP (pg/ml)         | 46.39 ± 36.90              | 37.10 ± 26.58             | 0.763*  |
| Progranulin (ng/ml)       | 53.75 ± 12.10              | 59.17 ± 17.42             | 0.172   |
| TG (mg/dl)                | 146.23 ± 57.66             | 190.62 ± 85.99            | 0.025*  |
| Insulin (muU/ml)          | 22.27 ± 5.88               | 48.72 ± 31.63             | <0.001* |
| Bile acids (µM)           | 3.17 ± 3.37                | 6.22 ± 5.84               | 0.003*  |
| Visceral adipose tissue markers (AU)* |                  |                           |         |
| CIDEA                     | 11.15 ± 9.34               | 14.25 ± 16.26             | 0.485   |
| CIDECE                    | 3.26 ± 1.83                | 4.61 ± 2.57               | 0.081   |
| PLIN                      | 7.11 ± 5.10                | 7.68 ± 6.23               | 0.774   |
| Lipoprotein lipase        | 1.56 ± 1.25                | 2.70 ± 2.88               | 0.239*  |
| HSD1B11                   | 45.28 ± 40.72              | 42.14 ± 45.10             | 0.846   |
| Sortilin                  | 29.83 ± 88.93              | 16.41 ± 13.66             | 0.222*  |
| GIPR                      | 1.45 ± 1.18                | 1.88 ± 1.63               | 0.521*  |
| Inflammatory markers (AU)*|                            |                           |         |
| PRGC                      | 22.92 ± 50.05              | 12.03 ± 15.70             | 0.692*  |
| FKN                       | 2.67 ± 2.53                | 4.44 ± 2.80               | 0.156   |
| OPN                       | 8.79 ± 7.95                | 14.97 ± 16.26             | 0.254   |
| ADAM17                    | 2.38 ± 1.26                | 4.30 ± 2.21               | 0.004*  |
| TIMP3                     | 11.52 ± 6.35               | 12.95 ± 7.85              | 0.354   |
| TNF-α                     | 3.18 ± 2.66                | 9.90 ± 12.65              | 0.004*  |
| CCL2                      | 22.73 ± 29.81              | 14.70 ± 13.54             | 0.689*  |
| CCL8                      | 12.76 ± 15.52              | 14.45 ± 12.31             | 0.187*  |
| CCL20                     | 13.64 ± 21.23              | 16.88 ± 22.26             | 0.717   |
| IL-1β                     | 2.74 ± 3.27                | 3.52 ± 2.30               | 0.498   |
| IL-6                      | 63.81 ± 106.69             | 64.12 ± 75.05             | 0.629*  |

Bold values mean significance of P < 0.05.
* AU = arbitrary units: Expression of the various genes in visceral adipose tissue was assessed by qRT-PCR and normalized to expression of housekeeping gene RPLPO.

For the analysis of parameters of serum and adipose tissue variables associated with HOMA, 16 patients with BMI <30 were excluded, leaving 59 patients with BMI >30 and measured HOMA. The study population was divided into two groups with lower and higher insulin sensitivity using the median HOMA value of 6. Importantly, the two groups had very similar age and BMI. The percentage of men was significantly higher among patients with a higher HOMA, and thus adjustment for gender was performed when testing the association with metabolic and inflammatory parameters that were different between groups.

The serum markers tested were several inflammatory adipose tissue-derived cytokines and adipokines, previously shown to be correlated with metabolic syndrome and insulin resistance [10,11]. However, the well-established serum markers did not differentiate between the two groups, with the exception of adiponectin, with levels reduced in the group with HOMA >6, albeit not significantly (P = 0.060) (Table 2).

Strikingly, bile acids levels were almost two-fold higher in group with HOMA >6 (P = 0.003) (Table 2). Of note, the significance was preserved even after adjustment to gender (OR = 1.21, 95% CI: 1.01–1.45, P = 0.044). Serum triglycerides were also significantly increased in the group with HOMA >6, but the significance was only borderline after adjustment to gender.

**Omental adipose tissue inflammatory variables associated with lower insulin sensitivity**

Table 2 presents data of omental tissue variables from patients that agreed to fat biopsies. In addition, values of parameters below detection levels were not included.

Expression of TNF-α, the inflammatory cytokine shown to be associated with inflammation-induced insulin resistance two...
decades ago [12], was indeed three-time higher \((P = 0.004)\) in the omental fat of the lower insulin sensitivity group (Table 2). Its significance was preserved after adjustment to gender (OR = 1.38, 1.04–1.84, \(P = 0.026\)).

A new player in obesity induced-insulin resistance is the enzyme ADAM17 [13], which among other substrates, cuts and releases the mature TNFα into the circulation [13]. Levels of ADAM17 mRNA were almost two-fold higher in the group with lower insulin sensitivity \((P = 0.004)\) (Table 2) and the association remained significant after adjustment for gender (OR = 1.93, 1.09–3.40, \(P = 0.024\)).

Importantly, when the variables that remained significantly associated with elevated HOMA with adjustment for gender were further tested together in a stepwise logistic regression, the strongest predictor that remained in the model was ADAM17 (OR = 1.82, 1.06–3.14, \(P = 0.031\)).

Analysis of inflammatory cytokines and chemokines in omental adipose tissue revealed strong positive correlations between two macrophage adhesion molecules, FKN and osteopontin (OPN) (Table 3). This association become even stronger \((r = 0.916, P = 0.001)\) when analysis was performed in the group with the lower insulin sensitivity. A remarkable significant positive correlation between levels of the two macrophage recruitment chemokines CCL2 and CCL8 and the inflammatory cytokine IL-1β was also observed (Table 3). The novel adipokine CCL20 [14] was also significantly positively correlated with the inflammatory cytokines and chemokines in omental adipose tissue (Table 3).

Lipid droplets proteins regulate the capacity of adipocytes to esterify fatty acids into triglycerides and store them within the cell in a safe manner [15]. Previous studies showed that higher expression of lipid droplet proteins perilipin, CIDEA and CIDEC were associated with higher insulin sensitivity in obese patients with similar BMI [16]. However, we have found no significant differences in the expression of lipid droplet proteins or in TG uptake enzyme lipoprotein lipase in the omental adipose tissue of both groups (Table 2).

### Correlation between omental adipose tissue PRGN, sortilin and IL-6

The novel adipokine PRGN has been shown to increase insulin resistance via induction of adipose tissue IL-6 [17]. Indeed, we have found a very strong positive correlation between omental adipose tissue expression of PRGN and IL-6 (Fig. 1). The trafficking molecule sortilin is known to regulate serum levels of PRGN by internalizing it and directing it to degradatory pathways [18]. For the first time, we show a strong positive correlation between the mRNA levels of these three factors in omental adipose tissue (Fig. 1). Of note, these correlations become even stronger in the group with lower HOMA: mRNA expression of PRGN and IL-6 \((r = 0.95, P < 0.001, n = 22)\); PRGN and sortilin \((r = 0.96, P < 0.001, n = 24)\); sortilin and IL-6 \((r = 0.93, P < 0.001, n = 22)\).

### Discussion

The present study highlighted the important role of serum bile acids as predictors of increased IR among morbidly obese patients. Furthermore, our results revealed ADAM17 as a novel and strongest predictor of IR in omental adipose tissue of morbidly obese patients.

Bile acids have beneficial effects on triglyceride metabolism and improve insulin sensitivity and whole body glucose homeostasis [19,20]. Indeed, post-prandial serum bile acids were found to be increased after Roux-en-Y gastric bypass [21]. Furthermore, the role of bile acids as general metabolic integrators was shown in a murine model in which bile acids administration increased energy expenditure of brown fat and prevented obesity and IR [22]. Surprisingly, our studies demonstrated increased levels of fasting bile acids in the group with lower insulin sensitivity (Table 2). These results of higher basal serum bile acids may reflect the impaired bile acids secretory function found in fatty liver disease [23]. Consistent with our results, serum bile acids were previously shown to be increased in diabetic obese patients [24].

In adipose tissue, the lower insulin sensitivity group displayed increased mRNA levels of inflammatory and metabolic markers. Numerous studies have highlighted the role of adipose tissue inflammation in obesity and IR [25–27].

Studies performed two decades ago recognized TNFα as a pivotal non-dispensable player in obesity-induced inflammation and IR [26,27]. The TACE/ADAM17 enzyme was shown to induce the shedding of TNFα, therefore participating in IR induction. A large body of evidence suggests that ADAM17 is activated in metabolic disorders and contributes to progressive deterioration of metabolic

### Table 3

| Correlation | FKN | OPN | CCL8 | CCL2 | IL1b |
|------------|-----|-----|------|------|------|
| OPN \(r\)  | 0.601 | 1   |      |      |      |
| \(P\)       | 0.001 |      |      |      |      |
| CCL8 \(r\)  | 0.213 | 0.313 | 1   |      |      |
| \(P\)       | 0.001 |      |      |      |      |
| CCL2 \(r\)  | 0.207 | 0.112 |      | 1    |      |
| \(P\)       | 0.049 | 0.119 | <0.001 |      |      |
| IL1b \(r\)  | 0.102 | 0.037 | 0.546 | 0.722 | 1    |
| \(P\)       | 0.645 | 0.861 | <0.001 | <0.001 |      |
| CCL20 \(r\) | 0.634 | 0.547 | 0.265 | 0.515 | 0.439 |
| \(P\)       | 0.002 | 0.005 | 0.136 | 0.002 | 0.015 |

Bold values mean significance of \(P < 0.05\).

**Figure 1.** Correlations between: (A) mRNA expression of PRGN and IL-6 \((n = 45)\); (B) PRGN and sortilin \((n = 49)\); (C) sortilin and IL-6 \((n = 45)\) in omental adipose tissue of obese patients. Expression of PRGN, sortilin and IL-6 was detected by qRT-PCR and normalized to expression of RPLPO.
homeostasis via regulation of pathways involved in adipose tissue infiltration by macrophages, reduction of glucose uptake in skeletal muscle and increased lipogenesis in the liver [13]. In our study, a stepwise logistic regression analysis of the variables significantly associated with elevated HOMA revealed that the strongest predictor for IR was ADAM17, with almost two-fold increased odds per one unit increase in ADAM17 levels. Furthermore, as expected, adipose tissue TNFα mRNA expression was another inflammatory marker associated with higher IR.

PRGN is an ubiquitously secreted protein, playing roles in cancer, wound healing and neurodegeneration [17,18,28]. Importantly, it was recently identified as a novel adipokine that participates in the induction of IL-6 secretion [17]. Indeed, our analysis of adipose tissue showed a strong association between mRNA expression of PRGN, IL-6 and also sortilin (Fig. 1). Sortilin, a trafficking molecule, regulates serum PRGN levels by directing it for degradation [29]. Here for the first time, we show an association between adipose tissue mRNA levels of sortilin and PRGN. Previous studies also support the concept of PRGN in IR, since elevated serum PRGN were associated with high levels of serum glucose and with omental obesity [30,31]. However, in our studies, we did not find any significant difference in serum PRGN levels in the two morbidity obese groups.

FKN and OPN, two chemokines involved in monocyte recruitment and adhesion and previously shown to be involved in IR [30–33], showed a two-fold increase in their mRNA expression in the omental adipose tissue of the morbidly obese patients with the lower insulin sensitivity, however this increase did not reach statistical significance, due maybe to the low number of subjects (Table 2). Notably, the expression of FKN was strongly associated with expression of OPN, and this association became even stronger in the group with lower insulin sensitivity (r = 0.916, P = 0.001).

Our study is limited by the fact that patients were recruited from the bariatric surgery clinic and all of them had some degree of IR, and therefore our cut-off was arbitrarily determined according to the median value of HOMA. Despite the markedly different HOMA averages of the two groups (4.46 ± 1.20 vs 12.53 ± 9.13), a study using “healthy obese patients” with HOMA < 2 may reveal stronger differences between the groups. Another limitation stems from the cross-sectional design of the study that prevents us from inferring the direction of the associations presented in this study.

Conclusions

Our study has examined several novel predictors of IR in morbidity obese patients, including serum bile acids and ADAM17, which may serve both as diagnostic markers and also may become useful targets for treatment of the metabolic syndrome in obese patients.

References

[1] Phillips CM. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocr Metab Disord 2013;14:219–27.
[2] Karelis AD. Metabolically healthy but obese individuals. Lancet 2008;372: 1281–3.
[3] Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Prud’homme D, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 2005;90:1415–50.
[4] Brochu M, Tchernof A, Doucette J, Sites CK, Etibakhah GH, Sims EA, et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab 2001;86:1020–5.
[5] Kuk JL, Ardern CI. Are metabolically normal but obese individuals at lower risk for all-cause mortality? Diabetes Care 2005;32:2297–9.
[6] Belleza AC, Dennis GV. Obesity genes and insulin resistance. Curr Opin Endocrinol Diabetes Obes 2010;17:47–27.
[7] Primeau V, Codere L, Karelis AD, Brochu M, Lavoie ME, Messier V, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond) 2011;35:971–81.
[8] Blumber M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr Opin Lipidol 2010;21:38–43.
[9] Bonora E, Targher G, Alberti MG, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57–63.
[10] Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 2005;22(Suppl. 2):3–10.
[11] Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347–55.
[12] Hotamisligil GS, Shargil NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1995;267:520–3.
[13] Menghini R, Fiorentino L, Casagrande V, Lauro R, Federici M. The role of ADAM17 in metabolic inflammation. Atherosclerosis 2013;228:12–7.
[14] Dufauff C, Zarkaroff-Girard A, Bourlier V, Decaunes P, Maumus M, Chiotasso P, et al. Macrophage-secreted cytokines and T lymphocytes in obesity: CCL20 as an adipokine and T lymphocytes as lipogenic modulators. Arterioscler Thromb Vasc Biol 2009;29:1608–14.
[15] Guilherme A, Vrabas J, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008;9:367–77.
[16] Puri V, Ranjit S, Konda S, Ncolomo SL, Straubhaar J, Chawla A, et al. Cidea is associated with lipid droplets and insulin sensitivity in humans. Proc Natl Acad Sci U S A 2008;105:7831–5.
[17] Matsubara T, Mita A, Minami K, Hosooka T, Kitazawa S, Takahashi K, et al. PRGN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab 2012;15:33–40.
[18] Zheng Y, Brady OA, Meng PS, Mau Y, Hu F. C-terminus of progranulin interacts with the beta-propeller region of sortilin to regulate progranulin trafficking. PloS One 2011;6:e21023.
[19] Chawla A, Repa JI, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001;294:1866–70.
[20] Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009;89:147–91.
[21] Kohli R, Bradley D, Setchell KD, Eagon JC, Abumrad N, Klein S. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab 2013:98:E708–12.
[22] Watanabe M, Houten SM, Matakai C, Christoffolete MA, Kim BW, Sato H, et al. Bile acids induce energy expenditure by intracellularly promoting thyroid hormone activation. Nature 2006;439:484–9.
[23] Ben-Shlomo S, Zvilb J, Rabinovich L, Goldiner I, Shlomo A, Santo EM, et al. Dipeptidyl peptide 4-deficient rats have improved bile secretory function in high fat diet-induced steatohepatitis. Dig Dis Sci 2013;58:172–8.
[24] Wewalka M, Patii ME, Barbato C, Houten SM, Goldberg AB. Fasting serum tauire-conjugated bile acids are elevated in type 2 diabetes: and do not change with intensification of insulin. J Clin Endocrinol Metab 2014 Apr;99(4):1442–51.
[25] Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 2011;11:738–49.
[26] Osborn O, Olesen YM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012;18:363–74.
[27] Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772–83.
[28] Chen K, Sephton CF, Karelis AD, Yu G. Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration. J Biol Chem 2012;287:32298–306.
[29] Hu F, Padukkavidana T, Vaegter CB, Brady OA, Zheng Y, Mackenzie IR, et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 2010;68:654–67.
[30] Youn BS, Bang SI, Kloting N, Park JW, Lee N, Oh JE, et al. Serum progranulin concentrations may be associated with macrophage infiltration into omental adipose tissue. Diabetes 2009;58:627–36.
[31] Hossein-Nezhad A, Mizraei K, Ansar H, Eman-Gholipour S, Tootee A, Klahrer S, Obesity, inflammation and resting energy expenditures: possible mechanism of progranulin in this pathway. Minerva Endocrinol 2012;37:255–66.
[32] Kloting N, Fasshauer M, Dietrich A, Kost C, Mihalkova S, Klein KL, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010;299:E506–15.
[33] Shah R, Hinkle CC, Ferguson JF, Mehta NN, Li M, Qu L, et al. Fractalkine is a novel human adipocytokine associated with type 2 diabetes. Diabetes 2011;60:1512–8.